Biotech | August 26, 2021
Adjuvance announce clinical results of its next-gen saponin adjuvant
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
The company to receive upfront and milestone payments, in addition to royalties
The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology
Domestic business was up 41.9% YoY and 27.7% QoQ
The company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures
Goal of providing 12-month internship opportunities for qualified students
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
This year, the company plans to set up more than 200 labs and 3000 collection centres across the world and has ended FY 21 with a revenue of Rs 800 crores
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
Subscribe To Our Newsletter & Stay Updated
